There was an excitement evident at this week’s meeting of stem cell scientists in Boston, with speakers highlighting how the years of toil in labs were approaching payoffs for patients, as more cell therapies have moved into clinical trials and researchers have gained a greater understanding of how to maximize their promise.
“This is our century,” Sally Temple, the president of the International Society for Stem Cell Research, said as thousands of experts milled about.
But amid the buzz, organizers made a point to call out what they see as a threat to both patients and to the legitimacy of the field as whole.
About the Author Reprints
